N/A N=50 Sensitivity of PDL-1-analysis From Pleural Effusion in Non-small Cell Lung Cancer
Lung Neoplasms
Primary: PD-L1 Prevalence IHC — 21; 14; 8; 27 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=30 Neoadjuvant Pembrolizumab
Non-small Cell Lung Carcinoma
Primary: Surgical Feasibility Rate as Measured by the Number of Subjects Who Undergo Surgery Following Neoadjuvant Pembrozulimab — 24 Participants
Phase 2 N=46 Preoperative Pemetrexed and Carboplatin for Select Stage IB, II, and III Non-Squamous Non-Small-Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: 3-Year Overall Survival Rate — 45 percentage of participants
Phase 2 N=71 Multimodality Treatment for Patients With Resectable Non-Small Cell Lung Cancer (NSCLC) - BEACON Study: Bevacizumab and Chemotherapy for Operable NSCLC
Carcinoma, Non-Small-Cell Lung
Primary: The Primary Goal of This Study is to Show That the Addition of Bevacizumab to Cisplatin-based Chemotherapy in the Neoadjuvant Setting for Non-squamous Cell Carcinomas…
Phase 2 N=30 Neoadjuvant Anti PD-1 Immunotherapy in Resectable Non-small Cell Lung Cancer
Non-small Cell Lung Cancer (NSCLC)
Primary: Number of Patients Treated in Compliance With Protocol — 29 Participants
N/A N=215 BEPACT- Lung: Impact of Patient Characteristics on Pneumo-oncologists Non Small Cell Lung Cancer (NSCLC) Systemic Treatment Decision in Belgium
Stage IV Non-small Cell Lung Cancer
Primary: The Study Outcome is Defined as the Systemic Treatment Choice. — 26; 68; 0; 99 Participants
N/A N=86 ENB-GS-TBLB for the Diagnosis of PPLs
Lung Cancer
Primary: The Difference of Diagnostic Value of ENB-GS-TBLB as Compared to GS-TBLB — 34; 25; 5; 16 participants — p=0.019
Phase 2 N=24 Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC)
Non Small Cell Lung Cancer
Primary: Percentage of Subjects With Detectable Circulating T Cells After Treatment — 16.7 Percentage of participants
Phase 3 N=72 Intrapleural Bevacizumab and Cisplatin Therapy for Malignant Pleural Effusion Caused by Non-small Cell Lung Cancer
Malignant Pleural Effusion
Primary: Number of Participants With "Complete Response" and "Partial Response" — 17; 2; 13; 15 participants
N/A N=6 Pathologic and Immunologic Response After Ablative Radiation in Lung Cancer
Non-small Cell Lung Cancer Stage I
Primary: Examine the T-cell Receptor Profile Changes Induced in the Tumor After SABR
Phase 2 N=30 Molecular Profiling in Lung Cancer Patients
Non-Small Cell Lung Cancer · Carcinoma
Primary: High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood
Phase 2 N=123 Durvalumab (MEDI4736) Plus Tremelimumab for Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin
Neuroendocrine Tumors · Neuroendocrine Neoplasm of Lung
Primary: Clinical Benefit Rate (CBR) — 0; 0; 0; 1 Participants
Phase 2 N=42 Neoadjuvant Platinum-based Chemotherapy for Patients With Resectable , Non-small Cell Lung Cancer With Switch to Chemotherapy Alternative in Nonresponders (NEOSCAN)
Lung Cancer
Primary: PERCIST Partial Metabolic Response — 6 participants
Phase 2 N=46 Neo-Adjuvant Immunotherapy With Nivolumab for Non Small Cell Lung Cancer Patients
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 77.1 percentage of participants
N/A N=55 Robotic Bronchoscopy for Peripheral Pulmonary Lesions
Lung; Node
Primary: Number of Participants With Device or Procedure Related Adverse Events — 2 Participants
N/A N=42 Assessment of the Effectiveness of Local Ablathermy Radio Frequency Bronchial Tumors Primitive
Malignant Non-small Cell Neoplasm of Lung Stage Ia
Primary: Local Tumor Control Rate 1 Year After Percutaneous Radiofrequency Ablation (RFA) — 5 Participants
Phase 1 N=6 Intratumoral Cisplatin for Resectable NSCLC
Non-Small Cell Lung Cancer
Primary: Rate of Dose Limiting Toxicity — 0 participants
N/A N=59 Mini Invasive Endomicroscopy of the Pleura for Malignancies Diagnosis
Pleural Diseases · Pleural Neoplasms
Primary: Malignant Pleural Infiltration Identification — 12; 27; 9; 4 Participants — p=0.023
N/A N=24 Pilot Study of Navigational Bronchoscopy and Transthoracic Needle Biopsy
Peripheral Pulmonary Nodules
Primary: Feasibility — 24 participants
Phase 2 N=12 Pembrolizumab With and Without Radiotherapy for Non-Small Cell Lung Cancer
Non Small Cell Lung Cancer
Primary: Change in the Mean Number of Infiltrating Absolute Cluster of Differentiation 3 (CD3+) T Cells/ μm2 — 2976.00007; 3768.74373 CD3+ T cells/ μm2
N/A N=25 Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients
Idiopathic Pulmonary Fibrosis
Primary: 6 Minute Walk Distance — -6.2; -15.3 meters
Phase 2 N=35 Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Lung Cancer, Non-Small Cell
Primary: Number of Participants Achieving Tumor Shrinkage Based on Change in Tumor Volume — 2; 33 participants
Phase 2 N=40 Pembrolizumab in Preventing Lung Cancer in Patients With Stage I-II Non-Small Cell Lung Cancer or High-Risk Pulmonary Nodules, the IMPRINT-Lung Study
Lung Non-Small Cell Carcinoma · Stage I Lung Cancer AJCC v8 · Stage IA1 Lung Cancer AJCC v8
Primary: 6-month CT Assessment (Tumor Response Per mRECIST) — 1; 36; 2; 1 Participants
Phase 2 N=22 Hyperpolarized Xenon Gas MR Imaging in NSCLC Radiotherapy
Non-small Cell Lung Cancer
Primary: Number of Participants With a Change From Baseline in Ventilation Map Using Hyperpolarized Xe-129 MR Imaging — 6 Participants — p=0.041
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
Phase 2 N=647 Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
Carcinoma, Non-Small-Cell Lung · Carcinoma, Small Cell Lung · Carcinoma, Thymic
Primary: Percentage of Enrolled Participants Testing Positive for Genomic Abnormality — 28.5; 44.2; 0; 24.9 percentage of participants
N/A N=15 The EMPrint™ Ablate and RESect Study in Patients With Metastatic Lung Tumors (EMPRESS)
Lung Cancer
Primary: Dose Response — -43.6; -15.1; -32.8; -63.5 percent difference
N/A N=204 The Detection Of Circulating Tumor Cells (CTC) In Patients With NSCLC Undergoing Definitive Radiotherapy Or Chemoradiotherapy
Non-small Cell Lung Cancer
Primary: To Describe the Pattern of CTCs Before and After Definitive Radiotherapy for Each Treatment Stratum — 3.9; 9.1; 9.1; 9.1 CTCs/mL
N/A N=74 A Volume, Motion, and Anatomically Adaptive Approach to Photon and Proton Beam Radiotherapy
Biopsy Proven Non Small Cell Lung Cancer · Head and Neck Cancer · Gastrointestinal Cancer
Primary: Tumor Volume — 93.55 cm^3
Phase 2 N=128 Sputum Labeling Utilizing Synthetic Meso Tetra (4-Carboxyphenyl) Porphine (TCPP) for Detection of Lung Cancer
Lung Cancer
Primary: Determine the Clinical Sensitivity and Specificity of the Biomoda CyPath™ Early Lung Cancer Detection Assay Using Sputum Specimens From Two Cohorts of Participants and…